These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10805349)

  • 1. Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial.
    de Seze J; Edan G; Labalette M; Dessaint JP; Vermersch P
    Ann Neurol; 2000 May; 47(5):686. PubMed ID: 10805349
    [No Abstract]   [Full Text] [Related]  

  • 2. Glatiramer acetate for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):61-2. PubMed ID: 9217693
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
    Blanco Y; Moral EA; Costa M; Gómez-Choco M; Torres-Peraza JF; Alonso-Magdalena L; Alberch J; Jaraquemada D; Arbizu T; Graus F; Saiz A
    Neurosci Lett; 2006 Oct; 406(3):270-5. PubMed ID: 16934924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
    Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena.
    Dufour A; Corsini E; Gelati M; Massa G; Tarcic N; Salmaggi A
    Ann Neurol; 2000 May; 47(5):680-2. PubMed ID: 10805344
    [No Abstract]   [Full Text] [Related]  

  • 6. Glatiramer acetate in multiple sclerosis.
    Mezzapesa DM; Rovaris M; Filippi M
    Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
    Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
    Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.
    Putheti P; Soderstrom M; Link H; Huang YM
    J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate (Copaxone).
    Francis DA
    Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).
    Johnson KP
    Mult Scler; 1996 Jul; 1(6):325-6. PubMed ID: 9345409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].
    Tsareva EIu; Kulakova OG; Makarycheva OIu; Boĭko AN; Shchur SG; Lashch NIu; Popova NF; Gusev EI; Bashinskaia VV; L'vov DV; Favorov AV; Ochs MF; Favorova OO
    Mol Biol (Mosk); 2011; 45(6):963-72. PubMed ID: 22295566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
    Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
    Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and MRI effects of Glatirameracetate].
    Nervenarzt; 1999 Aug; 70(8 Suppl):1-8. PubMed ID: 10511871
    [No Abstract]   [Full Text] [Related]  

  • 20. Glatiramer acetate: evidence for a dual mechanism of action.
    Blanchette F; Neuhaus O
    J Neurol; 2008 Mar; 255 Suppl 1():26-36. PubMed ID: 18317674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.